Adma Biologics reported $62.75M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Adma Biologics USD 62.75M 11.74M Dec/2025
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Novavax USD 20.94M 100.32M Dec/2025
Omeros USD -35.41M 23.75M Sep/2024
Takeda JPY -13.62B 182.44B Mar/2026